WO2002015884A3 - Rapidly disintegrating oral formulation of a cyclooxygenase-2 inhibitor - Google Patents

Rapidly disintegrating oral formulation of a cyclooxygenase-2 inhibitor Download PDF

Info

Publication number
WO2002015884A3
WO2002015884A3 PCT/US2001/025762 US0125762W WO0215884A3 WO 2002015884 A3 WO2002015884 A3 WO 2002015884A3 US 0125762 W US0125762 W US 0125762W WO 0215884 A3 WO0215884 A3 WO 0215884A3
Authority
WO
WIPO (PCT)
Prior art keywords
molded article
cyclooxygenase
inhibitor
oral formulation
rapidly disintegrating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/025762
Other languages
French (fr)
Other versions
WO2002015884A2 (en
Inventor
Tugrul T Kararli
Mark J Kontny
Trang T Le
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia LLC
Original Assignee
Pharmacia LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP01964122A priority Critical patent/EP1309315B1/en
Priority to DE60120710T priority patent/DE60120710T2/en
Priority to AU2001285011A priority patent/AU2001285011A1/en
Priority to MXPA03001407A priority patent/MXPA03001407A/en
Priority to CA002419592A priority patent/CA2419592A1/en
Priority to NZ524124A priority patent/NZ524124A/en
Application filed by Pharmacia LLC filed Critical Pharmacia LLC
Priority to JP2002520806A priority patent/JP2004506680A/en
Publication of WO2002015884A2 publication Critical patent/WO2002015884A2/en
Publication of WO2002015884A3 publication Critical patent/WO2002015884A3/en
Anticipated expiration legal-status Critical
Priority to CY20061101232T priority patent/CY1105319T1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Physiology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Pyrane Compounds (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

A molded article such as a tablet is provided for administration to an oral cavity of a subject to treat or prevent a cyclooxygenase-2 mediated condition, disorder or disease. The molded article comprises a moldable blend of a therapeutically effective amount of a selective cyclooxygenase-2 inhibitory drug with a pharmaceutically acceptable excipient carrier system consisting predominantly of one or more carbohydrates, wherein ingredients and amounts thereof in the molded article and a process for preparing the molded article are selected such that the molded article exhibits rapid disintegration in the oral cavity, and wherein the moldable blend is prepared by a process step not requiring wet granulation.
PCT/US2001/025762 2000-08-18 2001-08-17 Rapidly disintegrating oral formulation of a cyclooxygenase-2 inhibitor Ceased WO2002015884A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
DE60120710T DE60120710T2 (en) 2000-08-18 2001-08-17 FAST CRUMBLING ORAL DRUG PREPARATION CONTAINING VALDECOXIB
AU2001285011A AU2001285011A1 (en) 2000-08-18 2001-08-17 Rapidly disintegrating oral formulation of a cyclooxygenase-2 inhibitor
MXPA03001407A MXPA03001407A (en) 2000-08-18 2001-08-17 Rapidly disintegrating oral formulation of a cyclooxygenase-2 inhibitor.
CA002419592A CA2419592A1 (en) 2000-08-18 2001-08-17 Rapidly disintegrating oral formulation of a cyclooxygenase-2 inhibitor
NZ524124A NZ524124A (en) 2000-08-18 2001-08-17 Rapidly disintegrating oral formulation of a cyclooxygenase-2 inhibitor
EP01964122A EP1309315B1 (en) 2000-08-18 2001-08-17 Rapidly disintegrating oral formulation of valdecoxib
JP2002520806A JP2004506680A (en) 2000-08-18 2001-08-17 Rapid disintegrating oral preparation of cyclooxygenase-2 inhibitor
CY20061101232T CY1105319T1 (en) 2000-08-18 2006-08-30 VALDECOXIB ORAL RAPID PRESCRIPTION

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22648700P 2000-08-18 2000-08-18
US60/226,487 2000-08-18

Publications (2)

Publication Number Publication Date
WO2002015884A2 WO2002015884A2 (en) 2002-02-28
WO2002015884A3 true WO2002015884A3 (en) 2002-07-25

Family

ID=22849097

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/025762 Ceased WO2002015884A2 (en) 2000-08-18 2001-08-17 Rapidly disintegrating oral formulation of a cyclooxygenase-2 inhibitor

Country Status (14)

Country Link
US (1) US20020071857A1 (en)
EP (1) EP1309315B1 (en)
JP (1) JP2004506680A (en)
AT (1) ATE329583T1 (en)
AU (1) AU2001285011A1 (en)
CA (1) CA2419592A1 (en)
CY (1) CY1105319T1 (en)
DE (1) DE60120710T2 (en)
DK (1) DK1309315T3 (en)
ES (1) ES2265439T3 (en)
MX (1) MXPA03001407A (en)
NZ (1) NZ524124A (en)
PT (1) PT1309315E (en)
WO (1) WO2002015884A2 (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1429736A2 (en) * 2001-09-26 2004-06-23 Pharmacia Corporation Organoleptically acceptable intraorally disintegrating compositions
CN1602187A (en) * 2001-10-10 2005-03-30 法马西亚公司 Orally disintegrating valdecoxib composition prepared by spray drying
AU2002357046A1 (en) * 2001-12-07 2003-06-23 Merck And Co., Inc. Combination therapy comprising a cyclooygenase-2 inhibitor
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US7790905B2 (en) * 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
IL163846A0 (en) * 2002-03-01 2005-12-18 Univ South Florida Multiple-component solid phases containing at least one active pharmaceutical ingredient
IL165383A0 (en) * 2002-06-21 2006-01-15 Transform Pharmaceuticals Inc Pharmaceutical compositions with improved dissolution
US20060052432A1 (en) * 2002-09-20 2006-03-09 Julius Remenar Pharmaceutical compositions with improved dissolution
US8183290B2 (en) * 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
JP4739217B2 (en) * 2003-05-07 2011-08-03 サムヤン コーポレイション Highly plastic granules for making fast dissolving tablets
BRPI0302736B8 (en) * 2003-06-02 2021-05-25 Ems S/A pharmaceutical composition based on ketorolac or one of its pharmaceutically acceptable salts for sublingual use
US7282217B1 (en) 2003-08-29 2007-10-16 Kv Pharmaceutical Company Rapidly disintegrable tablets
US20050113410A1 (en) * 2003-11-03 2005-05-26 Mark Tawa Pharmaceutical salts of zafirlukast
WO2006070735A1 (en) * 2004-12-27 2006-07-06 Astellas Pharma Inc. Stable granular pharmaceutical composition of solifenacin or its salt
GB2423710A (en) 2005-03-01 2006-09-06 Boots Healthcare Int Ltd Lozenge production process
DE602006017188D1 (en) * 2005-03-07 2010-11-11 Bayer Schering Pharma Ag PHARMACEUTICAL COMPOSITION USING AN OMEGA CARBOXYARYL-SUBSTITUTED DIPHENYL HEAVEN IN THE TREATMENT OF CANCER
CN101222911A (en) * 2005-07-15 2008-07-16 特瓦制药工业有限公司 Novel granulation method and granules produced thereby
US8252329B2 (en) * 2007-01-05 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US9289583B2 (en) 2006-01-06 2016-03-22 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US9066847B2 (en) 2007-01-05 2015-06-30 Aceirx Pharmaceuticals, Inc. Storage and dispensing devices for administration of oral transmucosal dosage forms
US8357114B2 (en) 2006-01-06 2013-01-22 Acelrx Pharmaceuticals, Inc. Drug dispensing device with flexible push rod
US8535714B2 (en) 2006-01-06 2013-09-17 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8252328B2 (en) * 2006-01-06 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8865743B2 (en) 2006-01-06 2014-10-21 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8753308B2 (en) 2006-01-06 2014-06-17 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US8202535B2 (en) * 2006-01-06 2012-06-19 Acelrx Pharmaceuticals, Inc. Small-volume oral transmucosal dosage forms
WO2009021106A1 (en) * 2007-08-07 2009-02-12 Acelrx Pharmaceuticals, Inc. Compositions and methods for procedural sedation and analgesia using oral transmucosal dosage forms
US20100233272A1 (en) * 2007-11-15 2010-09-16 Leah Elizabeth Appel Dosage forms comprising celecoxib providing both rapid and sustained pain relief
EP2328510B1 (en) 2008-06-04 2014-10-15 Colgate-Palmolive Company Oral care implement with cavitation system
US20100075930A1 (en) * 2008-09-03 2010-03-25 Yoel Ovil Salicylic salt compositions and related method of treatment of cardiac conditions
US8945592B2 (en) 2008-11-21 2015-02-03 Acelrx Pharmaceuticals, Inc. Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US9259420B2 (en) * 2012-09-13 2016-02-16 Cba Pharma, Inc. Tetrandrine pharmaceutical formulations
BR112017013311B1 (en) 2014-12-23 2022-05-31 Acelrx Pharmaceuticals, Inc Device for dispensing oral and transmucosal dosage forms
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
US10350171B2 (en) 2017-07-06 2019-07-16 Dexcel Ltd. Celecoxib and amlodipine formulation and method of making the same
WO2019143432A1 (en) * 2018-01-21 2019-07-25 Kastner Bernie D Migraine treatment preparation and method
US12691128B2 (en) 2019-10-01 2026-07-28 Ellodi Pharmaceuticals, L.P. Methods of treating eosinophilic esophagitis and reducing candidiasis

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0396335A1 (en) * 1989-04-28 1990-11-07 Beecham Group p.l.c. Pharmaceutical formulation
US5501861A (en) * 1992-01-29 1996-03-26 Takeda Chemical Industries, Ltd. Fast dissolving tablet and its production
EP0748628A2 (en) * 1995-06-13 1996-12-18 American Home Products Corporation Oral formulations of S(+)-Etodolac
WO1997044028A1 (en) * 1996-05-17 1997-11-27 Merck & Co., Inc. Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases
WO1999004765A2 (en) * 1997-07-23 1999-02-04 Chiesi Farmaceutici S.P.A. Pharmaceutical compositions containing an effervescent acid-base couple
WO1999047172A2 (en) * 1998-03-13 1999-09-23 Recordati S.A. Chemical And Pharmaceutical Company Oral pharmaceutical compositions to be taken without liquids, which contain inclusion complexes
WO2000027382A2 (en) * 1998-11-12 2000-05-18 Merck & Co., Inc. Combination of a gaba-a alpha 5 inverse agonist and cox-2 inhibitor, nsaid, estrogen or vitamin e
WO2000032189A1 (en) * 1998-11-30 2000-06-08 G. D. Searle & Co. Celecoxib compositions
WO2001039749A2 (en) * 1999-11-30 2001-06-07 Panacea Biotec Limited Fast dissolving composition with prolonged sweet taste

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2109509C1 (en) * 1991-12-24 1998-04-27 Яманути Фармасьютикал Ко., Лтд. Composition for buccal administration of drug and a method of its preparing
US5567439A (en) * 1994-06-14 1996-10-22 Fuisz Technologies Ltd. Delivery of controlled-release systems(s)

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0396335A1 (en) * 1989-04-28 1990-11-07 Beecham Group p.l.c. Pharmaceutical formulation
US5501861A (en) * 1992-01-29 1996-03-26 Takeda Chemical Industries, Ltd. Fast dissolving tablet and its production
EP0748628A2 (en) * 1995-06-13 1996-12-18 American Home Products Corporation Oral formulations of S(+)-Etodolac
WO1997044028A1 (en) * 1996-05-17 1997-11-27 Merck & Co., Inc. Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases
WO1999004765A2 (en) * 1997-07-23 1999-02-04 Chiesi Farmaceutici S.P.A. Pharmaceutical compositions containing an effervescent acid-base couple
WO1999047172A2 (en) * 1998-03-13 1999-09-23 Recordati S.A. Chemical And Pharmaceutical Company Oral pharmaceutical compositions to be taken without liquids, which contain inclusion complexes
WO2000027382A2 (en) * 1998-11-12 2000-05-18 Merck & Co., Inc. Combination of a gaba-a alpha 5 inverse agonist and cox-2 inhibitor, nsaid, estrogen or vitamin e
WO2000032189A1 (en) * 1998-11-30 2000-06-08 G. D. Searle & Co. Celecoxib compositions
WO2001039749A2 (en) * 1999-11-30 2001-06-07 Panacea Biotec Limited Fast dissolving composition with prolonged sweet taste

Also Published As

Publication number Publication date
US20020071857A1 (en) 2002-06-13
ATE329583T1 (en) 2006-07-15
EP1309315A2 (en) 2003-05-14
CY1105319T1 (en) 2010-03-03
DE60120710T2 (en) 2007-06-14
CA2419592A1 (en) 2002-02-28
DE60120710D1 (en) 2006-07-27
PT1309315E (en) 2006-09-29
MXPA03001407A (en) 2003-06-06
JP2004506680A (en) 2004-03-04
AU2001285011A1 (en) 2002-03-04
WO2002015884A2 (en) 2002-02-28
EP1309315B1 (en) 2006-06-14
NZ524124A (en) 2004-09-24
ES2265439T3 (en) 2007-02-16
DK1309315T3 (en) 2006-10-09

Similar Documents

Publication Publication Date Title
MXPA03001407A (en) Rapidly disintegrating oral formulation of a cyclooxygenase-2 inhibitor.
MY128368A (en) Method for producing quickly decomposable solid pharmaceutical preparations
EP1120109A3 (en) Rapidly disintegrating and fast dissolving solid dosage form
WO2008120548A2 (en) Oral disintegrating tablet
MY121669A (en) Fast-dissolving galanthamine hydrobromide tablet
IL162271A0 (en) Pharmaceutical dosage form and method for the production thereof
PL341466A1 (en) Instantaneously spreading dised pharmacological preparation and method of forming granules
HUP0101282A1 (en) Tablets quickly disintegrating in the oral cavity and process for producing the same
WO2004069198A3 (en) Sugar-free oral transmucosal solid dosage forms and uses thereof
CA2990445A1 (en) Thermo-kinetic mixing for pharmaceutical applications
BR9712523A (en) New heterocyclyl-substituted pyrazole derivatives
WO2003047519A3 (en) 'compressed annular tablet with molded triturate tablet for oral and intraoral'
NO20070887L (en) Granular pharmaceutical formulation with time-limited release for oral administration, and intraoral rapid disintegrating tablet containing the preparation
MX9308188A (en) KONJAC GLUCOMANANE EASILY AVAILABLE, AS AN EXCIPIENT OF SUSTAINED LIBERATION.
WO2002024166A1 (en) Oral preparations with favorable disintegration characteristics
CO5170471A1 (en) MODIFIED RELEASE TABLETS INCLUDING AMOXYLIN AND POTASSIUM CLAVULANATE
WO2008142572A3 (en) Controlled release tablet formulation containing magnesium aluminometasilicate
WO2001043747A8 (en) Matrix tablet for prolonged release of trimetazidine after oral administration
WO2003082241A3 (en) Clarithromycin formulations having improved bioavailability
WO2004071374A3 (en) Once a day orally administered pharmaceutical compositions
WO2002092056A8 (en) Compaction process for manufacture of sodium phenytoin dosage form
BR0013106A (en) Floating pharmaceutical composition, tablet, and tablet preparation process.
CA2417709A1 (en) Compositions and dosage forms for application in the oral cavity in the treatment of mykoses
WO2001026621A3 (en) Orally distintegrating composition comprising mirtazapine
IL158216A0 (en) Disposable vaginal cannula for the simultaneous administration of drugs in different forms

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2001285011

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2001964122

Country of ref document: EP

Ref document number: 524124

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2419592

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/001407

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2002520806

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2001964122

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 524124

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 524124

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 2001964122

Country of ref document: EP